Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Dow
Harvard Business School
Medtronic
Colorcon
Express Scripts
Mallinckrodt

Last Updated: October 23, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Meticillin

See Plans and Pricing

« Back to Dashboard

Drug Development Status for Meticillin: Patents, clinical trial progress, indications

Meticillin is an investigational drug.

There have been 5 clinical trials for Meticillin. The most recent clinical trial was a Phase 3 trial, which was initiated on March 1st 2014.

The most common disease conditions in clinical trials are Peritonitis, Fibrosis, and Ascites. The leading clinical trial sponsors are Poitiers University Hospital, University of Padova, and Heidelberg University.

There are two US patents protecting this investigational drug and twenty-two international patents.

Recent Clinical Trials for Meticillin
TitleSponsorPhase
Open and Exploratory Trial to Investigate the Pharmacokinetic of Ceftobiprole Medocaril in Patients With CSF DeviceCentre Hospitalier Universitaire DijonPhase 2
Efficacy Study of Vitamin D Supplementation to Meticillin Resistant Staphylococcus Aureus (MRSA) CarriersPeter BergmanPhase 2
Population Pharmacokinetic (PK) Study of Multiple Doses of CubicinĀ® (Daptomycin) 10 mg/kg in Critical Care Patients Having Bacteremia, Endocarditis or Skin Soft Tissue Infections Due to Gram Positive Bacteria With Various Degrees of Renal FailurePoitiers University HospitalPhase 3

See all Meticillin clinical trials

Clinical Trial Summary for Meticillin

Top disease conditions for Meticillin
Top clinical trial sponsors for Meticillin

See all Meticillin clinical trials

US Patents for Meticillin

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Meticillin   Start Trial Phosphonate compounds for treatment of medical disorders Achillion Pharmaceuticals, Inc. (New Haven, CT)   Start Trial
Meticillin   Start Trial Monomethylvaline compounds having phenylalanine side-chain modification at the C-terminus Seattle Genetics, Inc. (Bothell, WA)   Start Trial
Meticillin   Start Trial Cyclic boronic acid ester derivatives and methods of making the same Rempex Pharmaceuticals, Inc. (San Diego, CA)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Meticillin

Drugname Country Document Number Estimated Expiration Related US Patent
Meticillin Taiwan 201718611 2035-08-26   Start Trial
Meticillin World Intellectual Property Organization (WIPO) 2017035357 2035-08-26   Start Trial
Meticillin Australia 2006269422 2025-07-07   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Express Scripts
Colorcon
Mallinckrodt
Baxter
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.